We are delighted by today's decision to allow patients with advanced prostate cancer to receive abiraterone on the NHS.
This drug was discovered at the Institute of Cancer Research and is the result of more than two decades of dedicated work by our scientists and and collaborators.
In clinical trials of men with advanced prostate cancer who have already tried chemotherapy, it has been shown to extend life by an average of four months and improve quality of life.
More top news
Nearly 500 identity frauds were reported every day in the first half od this year.
New position paper argues that it will be 'unnecessary' for the European Court to have direct jurisdiction in Britain after Brexit.
Demands for the government to deliver a fair deal on transport for the north of England will be made by political and business leaders.